Modality
ASO
MOA
BiTE
Target
BCMA
Pathway
NF-κB
RB
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
~May 2017
→ ~Aug 2018
Phase 2
~Nov 2018
→ ~Feb 2020
Phase 3
~May 2020
→ ~Aug 2021
NDA/BLA
~Nov 2021
→ ~Feb 2023
Approved
May 2023
ApprovedCurrent
NCT03511490
1,545 pts·RB
2023-05→TBD·Recruiting
1,545 total pts1 indication
CompletedCurrentUpcoming
Trial Timeline
Approved
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03511490 | Approved | RB | Recruiting | 1545 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| BII-8315 | Biogen | NDA/BLA | CDK2 |